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Abstract
Background: Serologic testing algorithms for recent HIV seroconversion (STARHS) provide important information
for HIV surveillance. We have shown that a patient’s antibody reaction in a confirmatory line immunoassay (INNO-
LIATM HIV I/II Score, Innogenetics) provides information on the duration of infection. Here, we sought to further
investigate the diagnostic specificity of various Inno-Lia algorithms and to identify factors affecting it.
Methods: Plasma samples of 714 selected patients of the Swiss HIV Cohort Study infected for longer than 12
months and representing all viral clades and stages of chronic HIV-1 infection were tested blindly by Inno-Lia and
classified as either incident (up to 12 m) or older infection by 24 different algorithms. Of the total, 524 patients
received HAART, 308 had HIV-1 RNA below 50 copies/mL, and 620 were infected by a HIV-1 non-B clade. Using
logistic regression analysis we evaluated factors that might affect the specificity of these algorithms.
Results: HIV-1 RNA <50 copies/mL was associated with significantly lower reactivity to all five HIV-1 antigens of the
Inno-Lia and impaired specificity of most algorithms. Among 412 patients either untreated or with HIV-1 RNA ≥50
copies/mL despite HAART, the median specificity of the algorithms was 96.5% (range 92.0-100%). The only factor
that significantly promoted false-incident results in this group was age, with false-incident results increasing by a
few percent per additional year. HIV-1 clade, HIV-1 RNA, CD4 percentage, sex, disease stage, and testing modalities
exhibited no significance. Results were similar among 190 untreated patients.
Conclusions: The specificity of most Inno-Lia algorithms was high and not affected by HIV-1 variability, advanced
disease and other factors promoting false-recent results in other STARHS. Specificity should be good in any group
of untreated HIV-1 patients.
Background
Information on HIV incidence is necessary for monitor-
ing the dynamics of the HIV epidemic in affected coun-
tries and assessing the effectiveness of preventive
measures targeted at major risk populations. Conse-
quently, serologic testing algorithms for recent HIV ser-
oconversion (STARHS) have been developed. These
tests make use of the fact that both the concentration
and affinity of HIV antibodies during the first few
months of HIV infection are lower than at later stages
[1-4]. STARHS require a special assay of reduced sensi-
tivity, hence they are also called ‘detuned’ assays. The
reduced sensitivity renders these tests unsuitable for
diagnosis of HIV infection and restricts their use to epi-
demiologic studies. For a systematic epidemiologic mon-
itoring it would be advantageous if information on the
proportion of recent infections could be gained prospec-
tively and systematically from the tests used anyway to
diagnose HIV infection.
We have shown that a patient’s antibody reaction in a
commercial line immunoassay, the Inno-LiaTM HIV I/II
Score (Inno-Lia), provides information on the duration
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of infection similar to that of a commercial enzyme
immunoassay (EIA) for STARHS, the so-called BED-EIA
[5,6]. The Inno-LIA is a kind of second-generation Wes-
tern blot and measures antibodies to different HIV anti-
gens in a semi-quantitative way. The pattern and
intensity of HIV-specific antibodies both evolve during
the first weeks to months after infection. It is thus pos-
sible to define algorithms which, with a certain diagnos-
tic sensitivity and specificity, recognize early and late
antibody patterns. Based on the number of cases ruled
recent by the Inno-Lia and the known values for sensi-
tivity and specificity it is then possible to calculate the
proportion of infections of up to 12 months duration in
a group by using a simple formula [5]. As the Inno-Lia
is a confirmatory HIV test, it is convenient to prospec-
tively test all newly diagnosed patients and to notify the
results to the respective health authority, which will cal-
culate periodically the proportion of recent infections
among the different transmission risk groups.
The diagnostic sensitivity and specificity of each algo-
rithm are crucial for this method. If they are not correct,
estimates of recent infections will not be accurate. We
estimated these parameters for a total of 12 algorithms
in a baseline study of newly diagnosed patients with
HIV-1 infection of either less or more than 12 months
duration, as judged by the treating physicians of these
patients. The estimates for sensitivity resulting from this
study varied between 20 and 50%, while specificity was
between 92 and 100%. The algorithm, which distin-
guished best between incident and older infection, had a
sensitivity of 50.3% and a specificity of 95.0% [5]. As the
study was prospective, it was difficult to know whether
the treating physician’s judgment on the duration of
each infection was correct. Follow-up information on
the patients on the course of HIV-1 RNA and CD4+ T
cell concentrations over time, which is sometimes neces-
sary for differentiating between severe primary and
advanced HIV infection, was not available at the time of
diagnosis, and the reliability of the staging information
in that first study is therefore somewhat arguable. For
example, some of the patients classified as CDC stage B
or C by the diagnosing physician, but ruled recent by
the Inno-Lia algorithms, may actually have suffered
from severe acute HIV infection [7-9]. Another well-
known cause for a false classification is infection by
non-B subtypes of HIV-1 [10,11]. Patients infected with
non-B viruses may produce antibodies of reduced avidity
to the subtype B antigens frequently employed in serolo-
gic tests, thus leading to false classification as recent.
Similarly, the waning antibody titers to some HIV pro-
teins in advanced immunodeficiency may lead to false
classification as recent infection [12-17].
Reliable information on the diagnostic performance of
our method is thus still lacking, and the true diagnostic
sensitivity and specificity of the Inno-Lia algorithms for
recent infection still have to be established. Towards
this goal, we have conducted two studies. One study, to
be published elsewhere, will determine the diagnostic
sensitivity in a cohort of patients diagnosed at the time
of primary HIV infection. That study will also investi-
gate the overall diagnostic performance of the algo-
rithms and present a validation of the method in
consecutive annual cohorts of HIV notifications.
In contrast, the goal of the present study was to
further assess the specificity of the algorithms in HIV-1
patients known to have been infected for longer than 12
months and to identify factors that might influence the
outcome of the algorithms. Of particular interest was
the question whether there was an impact by the HIV-1
subtype or an advanced stage of disease.
Methods
Ethics statement
This study was conducted as a nested project in the fra-
mework of the Swiss HIV Cohort Study (SHCS; see
http://www.shcs.ch ) [18]. The ethical committees of all
participating institutions, i.e., the HIV outpatient clinics
and laboratories of seven Swiss hospitals (the university
hospitals of Basel, Berne, Geneva, Lausanne, Zurich, and
the cantonal hospitals of Lugano and St Gallen), have
approved the general study protocol, and all participat-
ing patients have given their written informed consent
to the goals of the SHCS and its research projects,
including this one.
Patients and samples
The study investigated a single plasma or serum speci-
men from a total of 714 patients of the SHCS. The
patients and their specimens were selected for the study
in spring 2008. All patients had been infected with HIV-
1 for at least 12 months, as demonstrated by either a
documented first positive HIV test or registration into
the SHCS at least 12 months prior to sample date. The
patients originated from 7 different SHCS treatment
centers and represented all clinical stages and CD4+
strata. The HIV-1 subtype of all patients was known
based on the recorded results of genetic resistance test-
ing in the reverse transcriptase and protease regions of
the pol gene. Patients were selected with the aim that all
viral subtypes and circulating recombinant forms (CRF)
were represented with 30 samples both in CDC stages A
and B and with 40 samples in stage C. If there were
more patients of a given subtype per stage, the patients
required were selected randomly. If there were fewer, all
available were selected. Of all but 12 patients, a plasma
aliquot stored at -70°C was used for testing. For 12
patients a frozen serum sample stored at -20°C was used
instead.
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Serological differentiation of recent and older HIV-1
infection
All samples were number-coded and tested retrospec-
tively, batch-wise by the Inno-LiaTM HIV I/II Score
assay (Innogenetics, Ghent, Belgium). Testing was con-
ducted in 7 different accredited laboratories including 6
HIV regional confirmatory laboratories commissioned
by the Swiss Federal Office of Public Health (SFOPH)
and the Swiss National Center for Retroviruses (SNCR),
which serves as the national HIV reference laboratory
and is also commissioned by the SFOPH. All 7 labs are
accredited according to the international standard ISO/
IEC 17025 by the governmental Swiss Accreditation Ser-
vice SAS (see http://www.seco.admin.ch/sas/index.html?
lang=en). All had participated already in the first study
of Inno-Lia based recent infection assessment and were
experienced with the test [5].
The Inno-Lia is a Western blot-like line immunoassay
that measures antibodies against recombinant proteins
or synthetic peptides of HIV-1 group M, HIV-1 group
O, or HIV-2, which are coated as 7 discrete lines on a
nylon strip with plastic backing. As each test strip also
contains three quantitative internal standards, a semi-
quantitative ranking of the different antibody reactions
is possible [19,20].
All assays were performed between Oct 2008 and Jan
2009 and involved 4 different lots of test kits. The manu-
facturer’s 16-h sample incubation protocol was used for
all tests. In 3 labs, on a total of 498 samples, testing was
conducted on CE-marked Auto-Lia 48 or Autoblot 3000
test automats (both from Innogenetics). In 4 labs, on a
total of 216 samples, testing was performed manually.
Antibody reaction to each of the 7 HIV antigen bands
present on the test strips (sgp120 [including group O
peptides], gp41, p31, p24 and p17 of HIV-1, and sgp105
and gp36 of HIV-2) was assessed either visually (in three
of the four labs that used manual testing on a total of 123
samples) or by the automated scanner-based LiRAS sys-
tem (Innogenetics) (in 4 labs; 591 samples). Based on the
three internal standards, which define reaction levels of
0.5 (+/-), 1 and 3 for each test strip, the antibody reaction
to each HIV antigen was classified into one of six possi-
ble intensity scores (0, 0.5, 1, 2, 3, or 4).
Inno-Lia algorithms
Twenty-four algorithms (Algs) for recent HIV-1 infec-
tion were developed empirically by investigating which
Inno-Lia antibody patterns were found at maximal fre-
quency in a group of patients with less than 12 months
of infection (= recent or incident infections) and at
minimal frequency in a group of patients with ≥12
months duration of infection (= older infections).
Twelve of the algorithms, Alg02 to Alg13, are as pub-
lished [5]. The other 12 were developed more recently
based on the same dataset [5]. All 24 algorithms were
applied to the collected Inno-Lia data. Thus, each Inno-
Lia result was classified by 24 algorithms as representing
either a recent or older HIV-1 infection.
Data evaluation and statistics
The results of Inno-Lia testing and the clinical data of
the SHCS were linked only after all testing was com-
pleted. Differences between means were analyzed by the
nonparametric Mann-Whitney U test, differences in fre-
quency by contingency tables and Fisher’s exact test,
and correlations by nonparametric Spearman’s rank cor-
relation. Predictors of result of Inno-Lia algorithms
(incident or older infection) were evaluated by univariate
and multivariate logistic regression analysis. Indepen-
dents analyzed included person-related parameters (sex,
age, time since registration into the SHCS), disease-
related factors (CDC stage, CD4+ T-cell count and per-
centage, treatment status, duration of HAART, HIV-1
RNA concentration as by commercial RT-PCR assays
from Roche), and testing modalities (type of specimen,
storage duration, lot number of test kit, modes of testing
and result evaluation, laboratory which stored the sam-
ples and performed the testing). All statistical analyses,
as well as the classification of the Inno-Lia results by
the 24 recent infection algorithms, were performed in
the StatView 5.0 program for Macintosh (SAS Institute,
Cary, North Carolina, U.S.A.).
Results
A total of 714 stored plasma or serum samples from
patients who participated in the SHCS and had been
infected by HIV-1 for at least 12 months were tested by
the Inno-Lia HIV I/II score assay, as described under
Methods. The main epidemiological, virological and
immunological characteristics of the patients are sum-
marized in Table 1. Owing to the selection for non-B
clade infections, which in our country are more frequent
in women than in men, the two sexes were represented
at about equal numbers. Roughly half of the patients
were classified as CDC stage A, 22% were in stage B
and 28% in stage C. Almost three quarters of the
patients had received HAART for a median duration of
13.5 months, resulting in 308 patients who presented
with a HIV-1 RNA concentration below 50 copies/mL.
HIV-1 RNA among the 406 patients with HIV-1 RNA
≥50 copies/mL amounted to a median of 103.94 copies/
mL. The majority of the patients (86.8%) were infected
by non-B clades comprising a total of 15 different clades
in addition to subtype B.
Influence of HAART
The group of patients receiving HAART at the time of
testing had significantly lower concentrations of HIV-1
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RNA than those untreated (101.59 copies/mL compared
to 104.25 copies/mL; p < 0.0001, Mann-Whitney U test).
They also had significantly less intense reactions in the
Inno-Lia with respect to viral proteins sgp120 (p =
0.029), p31 (p < 0.0001), p24 (p = 0.0003) and p17 (p =
0.0013). In contrast, the intensity of antibodies to gp41
was similar in both treated and untreated patients (p =
0.17), and the minimal band intensity was 1.0 indepen-
dent of the treatment status. There was also a strong
association between viral load and band intensity (Figure
1). The 308 patients (including 6 who were treatment-
naïve) with HIV-1 RNA <50 copies/mL had on average
significantly lower intensity of all bands than the 406
patients with ≥50 copies/mL, particularly with respect to
sgp120, p31 and p17 (p < 0.0001 for all three) and
somewhat less with respect to gp41 (p = 0.003) and p24
(p = 0.008). The result of the Inno-Lia algorithms,
recent or older infection, was affected likewise by treat-
ment status and viral load (not shown). Multivariate
logistic regression analysis combining HIV-1 RNA,
treatment status and duration of HAART as indepen-
dents showed, however, that the treatment status and
the duration of HAART had no significant effect on the
result of any algorithm. In contrast, the viral load level -
more or less than 50 copies/mL - was a significant
determinant for outcome of all algorithms except Alg03,
Alg03.1, Alg05 and Alg06 (data not shown).
Based on these first findings we determined the diag-
nostic specificity of the 24 Inno-Lia algorithms among
the 190 treatment-naïve patients (including 6 patients
with HIV-1 RNA <50 copies/mL) and the 222 patients
with a viral load ≥50 copies/mL despite receiving
HAART. Algorithm specificity among these 412 patients
extended from 92.0% to 100%, with a median of 96.5%
(Table 2). Perfect specificity (100%) was obtained with
the single-band algorithms Alg03 and Alg03.1; Alg06
was least specific (92.0%). Specificity of the algorithms
among the 190 HAART-naïve patients alone was similar
(median 95.5%, range 93.2 – 100%).
Investigation of factors that affect algorithm specificity
Using logistic regression analysis, we sought to identify
the factors that affected the result of the various algo-
rithms in the total of the 714 patients. Alg03 could not
be analyzed, as it was 100% specific. Results for the
remaining 23 algorithms are summarized in Figures 2
and 3. There were predictors that promoted false-recent
results and others which protected against these. Most
of the effects were not distributed randomly, but were
associated with distinct groups of algorithms.
In the univariate analysis (Figure 2), the strongest and
most consistent predictors of algorithm result included
the HIV-1 RNA level, the CD4+ T cell percentage
(CD4%) or count, sex, HAART status, age, and CDC
stage. HIV-1 RNA <50 copies/mL, CD4% or count, age,
and receiving HAART promoted a recent infection
result. Other promoting factors included, in decreasing
Table 1 Patient characteristics
Patients (n, %) 714 100
Male (n, %) 345 48.3
Female (n, %) 369 51.7
Age, years (median, IQR) 35 30 - 42
Clinical stage
CDC A (n, %) 354 49.6
CDC B (n, %) 158 22.1
CDC C (n, %) 202 28.3
CD4+ T cell count, cells/μL (median, IQR) 350 220 - 533
CD4+ T cells, percent (median, IQR) 21.0 15.0 - 29.0
CD8+ T cell count, cells/μL (median, IQR) 808 565 -
1133
CD8+ T cells, percent (median, IQR) 51.0 41.0 - 59.0
Patients with HIV-1 RNA <50 copies/mL (n, %) 308 43.1
Patients with HIV-1 RNA ≥50 copies/mL (n, %) 406 56.9
HIV-1 RNA among these (log [copies/mL], IQR) 3.94 2.97-4.68
HIV-1 clade (n, %)
B 94 13.2
Non-B (15 different clades) 620 86.8
Treatment status
HAART-naive (n, %) 190 26.6
Receiving HAART (n, %) 524 73.4
Months on HAART if receiving HAART (median,
IQR)
13.5 11.1 - 17.8
-1
0
1
2
3
4
5
U
ni
ts
sgp120 gp41 p31 p24 p17
<.0001 <.0001 <.0001 .003 .008 
Figure 1 Effect of concentration of HIV-1 RNA on intensity of
Inno-Lia bands. The box-plots indicate the median (the “waist” of
the boxes) and the quartiles (upper and lower boundary of the
boxes); outliers above the 90th or, respectively, below the 10th
percentile (horizontal lines outside of the boxes) are plotted
individually as crosses. Numbers at the bottom indicate the p-values
of the Mann-Whitney U test for differences between patients with
HIV-1 RNA <50 copies/mL (lightly shaded; 308 patients) and ≥ 50
copies/mL (darkly shaded; 406 patients).
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Table 2 Specificity of 24 Inno-Lia algorithms among 412 patients either HAART-naïve or exhibiting HIV-1 RNA ≥50
copies/mL despite HAART
Alg # Definition N recent Specificity %
Single-band algorithms
2 if sgp120 ≤ 1
then RECENT
else older
16 96.1
3 if gp41 ≤.5
then RECENT
else older
0 100
3.1 if gp41 ≤ 1
then RECENT
else older
0 100
3.2 if gp41 ≤ 2
then RECENT
else older
6 98.5
4 if p31 = 0
then RECENT
else older
25 93.9
4.1 if p31 ≤ 0.5
then RECENT
else older
28 93.2
5 if p24 ≤ 0
then RECENT
else older
9 97.8
6 if p17 = 0
then RECENT
else older
33 92.0
Combined algorithms
7 if sgp120 + gp41 + p31 ≤ 4
then RECENT
else older
7 98.3
8 if gp41 ≤ 0.5
OR (sgp120 + gp41 + p31 ≤ 4)
OR (sgp120 + gp41 + p31 + p24 + p17≤ 6.5)
then RECENT
else older
13 96.8
8.1 if gp41 ≤ 0.5
OR (sgp120 + gp41 + p31 ≤ 4)
OR ((sgp120 + gp41 + p31 + p24 + p17≤ 6.5) AND p31≤1)
then RECENT
else older
13 96.8
9 if sgp120 + gp41 ≤ 4 AND p31 = 0
then RECENT
else older
7 98.3
10 if p31 = 0 AND p24 ≥ 2
then RECENT
else older
16 96.1
11 if (sgp120 + gp41 ≤ 2.5)
OR (sgp120 + gp41 + p31 + p24 + p17 ≤ 6.5)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
23 94.4
11.1 if (sgp120 + gp41 ≤ 2.5)
OR ((sgp120 + gp41 + p31 + p24 + p17 ≤ 6.5) AND p31≤1)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
23 94.4
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order, testing in certain laboratories compared to the
one taken as reference, a long duration of sample sto-
rage, or being infected with the circulating recombinant
form (CRF) CRF01_AE. Conversely, HIV-1 RNA con-
centration (in log(copies/mL), female sex or, for some
algorithms, being in CDC stages B or C compared to A
were factors that protected against a recent infection
result. Other protective factors for some algorithms
included being infected with CRF02_AG or subtypes A,
C or D, or manual Inno-Lia testing. There were also
some sporadic associations with the type or volume of
the stored specimen or lot number of test kit. No asso-
ciations were seen for duration of HAART, time since
registration into the SHCS and mode of result scoring
(visual versus automated).
The multivariate analysis of factors that affected algo-
rithm specificity (Figure 3) was performed with all para-
meters that had shown at least one significant
association in the univariate analysis. There was strong
co-linearity between CD4 count and CD4%, the two
parameters for HIV-1 RNA, as well as testing laboratory
and mode of testing. We therefore excluded CD4 count
and testing laboratory from the analysis. Regarding HIV-
1 RNA, we excluded log(copies/mL) in favor of the sta-
tistically stronger level.
The multivariate analysis confirmed the importance of
HIV-1 RNA, CD4%, sex and age. Specifically, for the 20
algorithms for which an effect of HIV-1 RNA was
demonstrated, <50 copies/mL was associated with a
roughly fivefold increase in false-recent results
Table 2 Specificity of 24 Inno-Lia algorithms among 412 patients either HAART-na?ï?ve or exhibiting HIV-1 RNA ?≥?50
copies/mL despite HAART (Continued)
12 if (p24 ≥ 2 AND p31 = 0)
OR (gp41 ≤.5)
OR (sgp120 + gp41 + p31 ≤ 4
OR sgp120 + gp41 + p31 + p24 + p17 ≤ 6.5)
then RECENT
else older
23 94.4
12.1 if (p24 ≥ 2 AND p31 = 0)
OR (gp41 ≤.5) OR (sgp120 + gp41 + p31 ≤ 4)
OR (p31 ≤ 1 AND (sgp120 + gp41 + p31 + p24 + p17 ≤ 6.5))
then RECENT
else older
23 94.4
13 if (sgp120 + gp41 ≤ 4 AND p31 = 0)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
17 95.9
13.1 if gp41 ≤ 2
OR (p31 = 0 AND p24 ≥ 2)
then recent
else older
20 95.1
14 if (sgp120 + gp41 + p31 + p24 + p17 ≤ 6.5 AND p31 ≤ 1)
then RECENT
else older
8 98.1
15 if (sgp120 ≤ 1 AND p31 ≤ 1)
OR (gp41 ≤ 2 AND p31 ≤ 1)
OR (p17 ≥ 2 AND p31 = 0)
OR (p31 = 0 AND p24 ≥ 2)
then RECENT
else older
18 95.6
16 if (sgp120 ≤ 1 AND (p31 + p24 + p17 ≤ 2.5))
OR (gp41 ≤ 1 )
OR (p31 ≤ 0.5 AND (sgp120 + gp41+ p24 + p17 ≥ 15))
OR (p24 = 0 AND gp41 ≤ 2 )
OR (p24 ≥ 3 AND p31 = 0 )
then RECENT
else older
12 97.1
17 if (sgp120 * gp41) ≤ 2
then RECENT
else older
4 99.0
18 if (sgp120 * gp41 ≤ 1)
OR (p24 + p31 = 0)
then RECENT
else older
5 98.8
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compared to a concentration ≥50 copies/mL (odds ratio
[OR]; mean, 4.85; range, 3.1 - 45.5). For the 18 algo-
rithms affected by CD4%, there was a mean 1.046fold
(range 1.025 - 1.083) increase in false-recent results for
each additional CD4%, i.e. by 4.6%. Women had a mean
2.4fold lower risk than men for the 13 affected algo-
rithms (mean OR, 0.412; range, 0.203 - 0.620). For age,
there was a 3.2% increase of false-recent results per
additional year with respect to the 11 marked algorithms
(mean OR, 1.032; range 1.021 - 1.043).
Furthermore, for those algorithms in which age pro-
moted a false-recent result, the testing of serum stored
at -20°C instead of plasma stored at -70°C appeared to
be a further promoting factor. There were only 12
serum samples, however, thus relativizing this finding.
Advanced clinical stage lost the protective effect seen in
univariate analysis in all algorithms but one. Sample
size, duration of sample storage, and modes of testing
and result evaluation retained no significance. Test kit
lot #3 was again associated with a lower specificity when
using Alg07 or, as a trend, Alg13.1. Close inspection of
the data showed, however, that the great majority of the
samples, namely 671 (86.4%), had been tested with lot
#1. Only 32 specimens (4.5%) had been tested with lot
#3, too few to permit any conclusions regarding possible
variations in lot quality.
No influence by HIV clade
Compared to HIV-1 subtype B, infection with
CRF01_AE remained significantly associated with an
increased proportion of false-recent results by Alg02,
Alg03.2, Alg07 and, as a trend, Alg17. Closer inspection
Al
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9
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g1
0
Al
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1
Al
g1
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1
Al
g1
2
Al
g1
2.
1
Al
g1
3
Al
g1
3.
1
Al
g1
4
Al
g1
5
Al
g1
6
Al
g1
7
Al
g1
8
Sex: female vs. male 0.031 0.088 0.003 0.001 0.003 0.003 0.001 0.002 0.003 0.017 0.031 0.026 0.044 0.075 0.070 0.021 0.039 0.028 0.005
Age (y) 0.044 0.085 0.025 0.069 0.016 0.019 0.017 0.023 0.021 0.023 0.002 0.003 0.032
CDC stage A
CDC stage B 0.091 0.074 0.075 0.087 0.050
CDC stage C 0.063 0.028 0.038 0.048 0.014 0.075 0.017 0.050 0.050 0.044
CD4+ count 0.021 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.005 0.003 0.002 0.001 0.000 0.000 0.000 0.000 0.001 0.013
CD4% 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.014 0.000 0.006
HIV-1 RNA, <50 cc./mL 0.000 0.000 0.000 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.003 0.000 0.000
HIV-RNA, log copies/mL 0.002 0.001 0.002 0.003 0.003 0.002 0.003 0.010 0.007 0.001 0.002 0.001 0.001 0.004 0.000 0.037 0.001 0.045 0.004 0.013
HAART 0.036 0.007 0.017 0.099 0.057 0.077 0.041 0.054 0.027 0.036 0.096 0.086 0.082 0.023
HAART duration
Time since registration
 Lab 1
 Lab 2
 Lab 3 0.063 0.082
 Lab 4 0.073
 Lab 5 0.095 0.027 0.095 0.051 0.051 0.096 0.096 0.054 0.096 0.051
 Lab 6 0.071 0.047 0.040 0.040 0.076 0.076 0.076
 Lab 7 0.020 0.066 0.094 0.038 0.051 0.014 0.005 0.020 0.008 0.038 0.014 0.038 0.020
 Lab 8 0.033 0.086 0.086 0.033 0.039 0.045 0.053 0.051 0.053 0.099 0.033
Serum vs. plasma 0.027 0.045 0.100 0.081 0.078
Sample volume 0.001 0.054
Storage, per year 0.006 0.099 0.000 0.070 0.086
Testing, manual vs. autom. 0.051 0.023
Scoring, visual vs.autom.
Lot of test kit 1
2
3 0.014 0.032
4
HIV Clade (n)      B (94)
CRF01_AE (92) 0.001 0.010 0.065 0.034 0.034
CRF02_AG (96) 0.009 0.009 0.082 0.033 0.050 0.050 0.050 0.099 0.099
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Figure 2 Univariate logistic regression analysis of factors that promote or impair algorithm specificity in all 714 patients. The meaning
of the colors is explained at the bottom of the figure. Numbers indicate the chi-square p-value of the respective variable analyzed. HIV-1 RNA
was used as a dichotomized parameter (<50 or ≥50 copies/mL).
Schüpbach et al. BMC Infectious Diseases 2011, 11:254
http://www.biomedcentral.com/1471-2334/11/254
Page 7 of 13
of the data showed that these associations were largely
restricted to patients receiving HAART. For example,
with Alg02, among treated patients, there were 17 false-
recent results among 71 patients infected with
CRF01_AE (24%) compared to 2 of 62 (3.2%) infected
with subtype B (p = 0.0008, Fisher’s exact test). In con-
trast, among untreated patients, the respective figures
were 3/21 for CRF01_AE compared to 2/32 for subtype
B (p = 0.37). Thus, only 3 of the 20 false-recent results
were among treatment-naïve patients, too few to permit
any safe conclusion.
Similarly, the apparent protective effects of infections
by CRF02_AG or subtypes A, C and D also turned out
to be associated with HAART. With Alg04, e.g., there
were 13 false-recent results among 62 treated patients
infected with subtype B (21%), while the respective
numbers for CRF02_AG were 4/72 (5.6%). Thus, among
treated patients, those infected with CRF02_AG had a
significantly lower risk for false-recent results than those
infected with subtype B (p = 0.009). In contrast, among
untreated patients, the proportions of false-recent results
between CRF02_AG (1/24, 4%) and subtype B (4/32,
12.5%) differed less (p = 0.38). Again, only 5 of the
false-recent results occurred among HAART-naïve
patients. Similar relationships were found with respect
to the apparent protective effects of subtypes A, C and
D compared to B (not shown).
In a next step to determine the relevance of the fac-
tors leading to false-recent results, we narrowed the
analysis to those 412 patients who were either HAART-
naïve or exhibited HIV-1 RNA ≥50 copies/mL despite
receiving HAART (Figure 4). The analysis was further
restricted to those independents which in Figure 3 had
shown significant effects with at least two algorithms.
Thus, CDC stage, HAART, sample volume, storage
duration, modes of testing and scoring, and kit lot were
no longer in the model. Alg03.1 had no false-recent
result and could not be analyzed.
Age impairs algorithm specificity
The only variable that retained broad significance in this
setting was age, which significantly promoted false-
recent results in 6 algorithms and showed a trend in a
further 8. On average, the rate of false-recent results
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Figure 3 Multivariate logistic regression analysis of factors that affect algorithm specificity in all 714 patients. The meaning of the
colors is explained at the bottom of the figure. Numbers indicate the chi-square p-value of the respective variable analyzed. Odds ratios of
variables of particular interest and their 95% confidence intervals are shown in the text. HIV-1 RNA was used as a dichotomized parameter (<50
or ≥50 copies/mL).
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among these 14 algorithms increased by 5.2% for each
additional year (range, 2.6 - 8.8%). CD4% lost all signifi-
cance. HIV-1 RNA retained trends for significance with
Alg 4.1 (OR, 0.74; 95% CI 0.52 - 1.04) and Alg16 (OR,
0.63; 95% CI 0.37 - 1.07). Although HIV-1 RNA was far
away from significance in all other algorithms, the
respective OR were usually below 1.0, particularly for all
16 combined algorithms, where the average OR per
additional log RNA was 0.75. Thus, a certain influence
of this parameter remains possible despite the lack of
individual statistical significance. HIV clade also lost
significance - note that the effect of CRF11_CPX with
Algs 10 to 13.1, 15 and 16 is based on only 2 cases.
Even more than in Figure 3, the remaining weak trends
for either promoting or protective effects are based on
too few cases to be of any relevance.
When finally focusing the investigation on the 190
HAART-naïve patients, univariate analysis revealed age
as a factor, which significantly promoted false-recent
results in four algorithms and showed a trend in two
further ones (Figure 5, top panel). CD4% and HIV-1
RNA had no clear effects; a higher viral load even
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promoted false-recent results in Alg06. All other factors
had no significance and are not represented in the fig-
ure. Multivariate analysis confirmed most effects of the
three independents (lower panel). CD4% showed addi-
tional weak protective effects with Alg07 and Alg09,
while HIV-1 RNA showed further protective effects with
Algs 07, 09, 10, 16, and 17. Age lost its effect with
Alg06, but gained a new one with Alg 10. Exclusion of
the 6 cases with HIV-1 RNA <50 copies/mL led to the
loss of all protective effects of HIV-1 RNA, while the
effects of age and CD4% remained. This suggested that
HIV-1 RNA <50 copies/mL promoted false-recent
results also among untreated patients, while there was
no effect among the higher concentrations. With regard
to CD4%, close inspection of the data revealed no evi-
dence for an association of low CD4% with low antibody
intensities, and antibody intensities among patients in
CDC stage C were on average higher than in stage A.
Therefore, the weak effects of CD4% were not attributa-
ble to patients in advanced stage of disease.
In cross-comparison of Figures 3, 4 and 5, age clearly
promoted false-recent results in all groups. Independent
of the statistical significance in individual algorithms,
the mean odds ratio for age among the algorithms dif-
fered little between the analyses of Figures 3, 4, and 5
and amounted to 1.021, 1.037 and respectively 1.032,
thus suggesting a relative increase in false-recent results
of about 3% per additional year of life. An HIV-1 RNA
below 50 copies/mL promoted false-recent results in
both treated and untreated patients; above this level
there was, however, no effect of the concentration. With
respect to CD4%, the strongly promoting effect in Figure
3 was strictly associated with long-term, successful
HAART, as it was no longer present when HIV-1 RNA
was above 50 copies/mL or when patients were
HAART-naïve (Figure 5). If the weak protective effects
in this latter group are real, they were not attributable
to patients in the most advanced stage of disease. All
other factors, including HIV-1 clade, had no effect.
Discussion
The principal goal of the study was to determine the
specificity of more than 20 Inno-Lia algorithms devel-
oped for estimating the fraction of recent infections in
cohorts of HIV-1 infected patients [5]. A second aim
was to identify possible factors that impair the specificity
of the algorithms. Of particular importance was whether
non-B clades of HIV-1 or advanced stages of immune
deficiency would lead to false-recent results. These
investigations are a first step of an ongoing overall eva-
luation of this new method, and without full knowledge
of the sensitivity of the algorithms and their overall per-
formance, which are investigated in a separate study to
be published elsewhere, no definite conclusions should
be drawn as to the suitability of this method for assess-
ment of the recent infection rate in a population.
In order to answer the questions addressed in the pre-
sent study, we retrospectively tested frozen specimens
from well-characterized patients of the SHCS [18]. All
patients, 86.8% of them selected for infection with non-
B clades of HIV-1 and 73.4% receiving HAART for a
median duration of more than one year, were in the
chronic stage of infection and had been infected for
longer than 12 months (Table 1). These 714 patients
clearly represented older HIV infections as by our defi-
nition [5] and provided suitable conditions for an analy-
sis of factors that affected algorithm specificity.
The high specificity of the 24 Inno-Lia algorithms
(Table 2) already indicated that HIV-1 clade could have
but a small effect. This was confirmed by univariate and
multivariate logistic regression analysis (Figures 2 and
3). Both showed that the non-B clades that were avail-
able at sufficiently high numbers, i.e., subtypes A, C, D,
F, G and J, as well as CRF01_AE, CRF02_AG and
CRF06_CPX, did not affect the specificity in a relevant
manner. Apparent promoting effects of CRF01_AE for
false-recent results in Algs 02, 03.2, 07 and 17 were
upon closer inspection found to be restricted to patients
receiving HAART. Similarly, apparent protective effects
of CRF02_AG and subtypes A, C and D were also
restricted to patients receiving HAART. Both types of
effects lost significance when the analysis was restricted
to patients with no or only incompletely effective
HAART. We conclude that these effects were largely
treatment-associated and will not exert a sizeable effect
in newly diagnosed, untreated patients.
In contrast to virus clade, there were some para-
meters, which affected the algorithms in a consistent
and highly significant manner. One of these predictors
was HIV-1 RNA <50 copies/mL, which was associated
with a lower antibody intensity against all five HIV-1
antigens (Figure 1) and promoted false-recent results in
most algorithms (Figure 3). HIV-1 RNA retained no sig-
nificance when restricting the analysis to patients with
no or incompletely effective HAART (Figure 4), thus
confirming that only a very low or undetectable viral
load would lead to false-recent results.
Our finding that HAART or, respectively, the low or
undetectable viral load resulting from prolonged
HAART was associated with a reduction in the concen-
tration of HIV-specific antibodies in chronically infected
patients is in contradiction to other reports. Although
several studies have shown a delayed seroconversion, or
partial seroreversion, in patients in whom HAART was
started during acute infection or shortly thereafter
[21-25], two studies of about 80 patients each found no
reduction of HIV antibodies in chronically infected
patients successfully treated with HAART for at least 5
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years [24,25]. In contrast to these two studies and
despite a shorter treatment duration, the average inten-
sity of all five HIV antibody specificities in patients with
<50 copies/mL HIV-1 RNA under HAART was signifi-
cantly lower in the present study (Figure 1). This indi-
cates a modest, but clear effect of HAART on antibody
concentrations in chronically infected patients.
A high CD4% (or CD4+ count) was another factor
strongly associated with false-recent results in the analy-
sis of all 714 patients (Figure 3). This association is
more difficult to understand and is probably the result
of several superimposed effects. Further analysis revealed
that patients who were receiving HAART and had
higher CD4% than the median (≥21.4%) showed signifi-
cant inverse correlations between CD4% and all antibo-
dies except those to p24 (Spearman’s rank correlation; p
< 0.01 in all instances). In contrast, HAART-naïve
patients or those with CD4% below the median did not
exhibit such a correlation. In combination, these results
may suggest that the association of high CD4% and low
antibodies is an effect of HAART, whereby the patients
that regain the highest CD4% are also those most likely
to experience a decrease in their HIV-specific antibo-
dies. The fact that CD4% had no significance in Figure 4
and even exhibited some protective effects in Figure 5
suggests that its promotion of false-recent results in Fig-
ure 3 is also a treatment-associated artifact. In HAART-
naïve patients, a high CD4% may possibly protect
against false-recent results in certain algorithms, but
there was no indication that the patients with the most
advanced disease were prone to false-recent results.
Sex, age, and testing serum instead of plasma were
further frequent predictors of a false-recent result when
investigated in the entire collective (Figure 3). Age pro-
moted false-recent results in all algorithms that con-
tained the term ‘p31 = 0 AND p24≥2’ (Algs 10 to 13.1,
15 and 16; see Table 2). Patients older than 35 years
had twice as many false-recent results with Alg10 than
the younger ones (9.9% vs. 4.6%, Fisher’s exact test p <
0.01). They also exhibited a significantly lower mean
intensity of p31 antibodies (p < 0.01). Age retained sig-
nificance in the analyses of Figures 4 and 5 and exhib-
ited similar average odds ratios between all analyzed
groups. It is thus a factor that should also lead to some
false-recent results in newly diagnosed patients. This
finding fits into the well-known age-dependent weaken-
ing of the antibody responses to viral antigens such as
present in viral vaccines [26-29].
Other factors including sex, using different lots of test
kits, or testing serum instead of plasma, which appeared
to affect the specificity of some algorithms when tested
in all 714 patients (Figure 3), lost all significance when
tested in HAART-naïve patients or those with a viral
load ≥50 copies/mL despite HAART (Figure 4). As
these factors are logically independent of HAART, they
should also have no relevance when testing untreated
patients.
Limitations
For assessment of specificity of the algorithms and of
factors that may affect specificity, a cohort of untreated
patients would have been optimal. HAART has been the
standard of care for patients with a certain degree of
immunodeficiency for more than a decade, however,
and it was impossible to meet this goal. Only 190
patients were HAART-naïve and only 20 of them were
in CDC stage C.
Nevertheless, we consider our results to be valid for
newly diagnosed, untreated patients, for the following
reasons: Since HAART reduces the viral load and
because an undetectable viral load in turn is associated
with weaker antibodies, the antibody reactions in
untreated patients will be stronger, which should result
in even fewer false-recent results than found here. As a
matter of fact, when the 714 patients were stratified
according to CDC stage, the individual antibody intensi-
ties, as well as their sum, were higher in the untreated
patients in all stages. Similarly, when stratification was
for CD4% higher or lower than the median, the
untreated patients had higher antibody intensities,
except for p24, but the sum of all antibodies was higher
again. This illustrates that single band patterns that
would promote a false-recent result are successfully
‘diluted out’ or counteracted by suitably defined combi-
nation algorithms. Of note, some combination algo-
rithms, in particular Alg14, but also Algs 11 to 13.1,
appeared to be affected very little by all investigated
variables.
Nevertheless, we cannot exclude the possibility that
other factors than those investigated here may affect the
specificity of the method. It is thus advisable to pre-
determine the diagnostic performance of the test before
transferring it to a new setting.
Conclusions
The present study shows that the specificity of more
than 20 Inno-Lia algorithms for recent infection is high.
The specificity was clearly impaired by increasing age
and an HIV-1 RNA load below 50 copies/mL, but not
by the HIV-1 clade. Other variables, including sex, CDC
stage, HAART without effective virus control, modalities
of testing and result evaluation, did not matter. Simi-
larly, for most algorithms there was no evidence for
impairment by low CD4%. Some algorithms remained
largely unaffected by all variables. We therefore expect
that these algorithms should have a high specificity in
all possible settings of untreated HIV-1 infected patients.
Provided that they also exhibit a good diagnostic
Schüpbach et al. BMC Infectious Diseases 2011, 11:254
http://www.biomedcentral.com/1471-2334/11/254
Page 11 of 13
sensitivity and good overall performance, which are both
assessed in a different study, they might become valu-
able tools for monitoring the rate of recent HIV-1 infec-
tions among newly diagnosed patients.
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